What’s Next for Guardant Health, Inc. (GH) After Today’s Significant Decline?

The stock of Guardant Health, Inc. (NASDAQ:GH) is a huge mover today! The stock decreased 2.16% or $1.6 during the last trading session, reaching $72.39. About 1.44 million shares traded or 52.91% up from the average. Guardant Health, Inc. (NASDAQ:GH) has 0.00% since April 11, 2018 and is . It has underperformed by 4.37% the S&P500.
The move comes after 7 months negative chart setup for the $6.22B company. It was reported on Apr, 11 by Barchart.com. We have $69.49 PT which if reached, will make NASDAQ:GH worth $248.80 million less.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

More notable recent Guardant Health, Inc. (NASDAQ:GH) news were published by: Seekingalpha.com which released: “Midday Gainers / Losers – Seeking Alpha” on March 13, 2019, also Nasdaq.com with their article: “The GH Paradox: Analysts Bullish But Forecast -26.26% Fall – Nasdaq” published on March 18, 2019, Benzinga.com published: “Jim Cramer Weighs In On Alibaba, Kimberly Clark And More – Benzinga” on March 20, 2019. More interesting news about Guardant Health, Inc. (NASDAQ:GH) were released by: Nasdaq.com and their article: “7 Low Price-to-Sales Stocks to Buy for a Rewarding Portfolio – Nasdaq” published on April 02, 2019 as well as Nasdaq.com‘s news article titled: “Health Care Sector Update for 04/10/2019: PTE,IMMU,GH,OTLK – Nasdaq” with publication date: April 10, 2019.

Guardant Health, Inc., a precision oncology company, provides non-invasive cancer diagnostics. The company has market cap of $6.22 billion. It offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes from circulating tumor DNA ; and GuardantOMNI, a broader panel measuring various genes from ctDNA. It currently has negative earnings. The firm also provides LUNAR-1 for recurrence detection in cancer survivors; and LUNAR-2 for early detection of cancer in higher risk individuals.